Identification of Microbial Properties Predicting a Worsening Course of Fatty Liver Disease
NCT ID: NCT03748511
Last Updated: 2023-03-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
62 participants
OBSERVATIONAL
2019-03-05
2022-09-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Early Detection of Advanced Fatty Liver Disease
NCT03608748
Fatty Liver and Ectopic Fat in Overweight and Obese Patients
NCT00886301
Prospective Cohort, With Biobanking, of Patients With Nonalcoholic Fatty Liver Disease
NCT02422238
Prospective Cohort Study in Patients With NAFLD
NCT00575133
Non-invasive Evaluation of Liver Fibrosis, Steatosis, and NASH in NAFLD
NCT03725631
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
fatty liver disease 0-1F
20 patients with uncomplicated liver disease, with fibrosis stage 0-1F.
fibroscan and stool sample
patients undergo ultrasaound (fibroscan) in order to stage the liver disease.
fatty liver disease 2F
20 patients with liver disease, fibrosis stage 2F.
fibroscan and stool sample
patients undergo ultrasaound (fibroscan) in order to stage the liver disease.
fatty liver disease 3-4F
20 patients with advanced liver disease, fibrosis stage 3-4F.
fibroscan and stool sample
patients undergo ultrasaound (fibroscan) in order to stage the liver disease.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
fibroscan and stool sample
patients undergo ultrasaound (fibroscan) in order to stage the liver disease.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients who give approval to participate in the study
Exclusion Criteria
* acute or chronic kidney failure
* heart failure ( NYHA 3-4)
* active cancer
* fatty liver due to non alcoholic etiology.
* patients who consume drugs from the estrogen/methotrexate family, or chloroquine.
* history of hypothyrodism or cushing.
* patients who used TPA in the last 6 months .
* pathients with chronic liver disease like A1AT, hemochromatosis, wilson, toxic damage and autoimmunity .
* special population like - children, pregnant women and patients who lack the ability to make judgment.
* infectious liver disease - viral hepatitis or HIV.
* inflammatory bowel disease.
* patients who underwent surgery of the gastrointestinal trant.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
HaEmek Medical Center, Israel
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rawi Hazzan
Head of Liver Unit
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Liver Init
Afula, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
179-17-EMC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.